(±)-CPSI-1306 是一种巨噬细胞迁移抑制因子 (MIF) 拮抗剂，可用于关于非胰岛素依赖型糖尿病 (NIDDM) 的研究以及预防急性和慢性 UVB 暴露对皮肤的有害影响。

(±)-CPSI-1306 is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.

In mice, (±)-CPSI-1306 decreases their blood glucose levels and can be effective in treating non-insulin-dependent diabetes mellitus (NIDDM) as characterized by high serum levels of glucose and inflammatory cytokine[1]. (±)-CPSI-1306-induced keratinocyte apoptosis is appreciated 30 minutes after a single UVB exposure. (±)-CPSI-1306-treated mice show a significant increase in expression of cleaved caspase-3 at 6, 24, and 48 hours following UVB exposure. (±)-CPSI-1306 reduces acute UVB-induced keratinocyte DNA damage and UVB-induced acute inflammation[2].

1309793-47-2

C15H16F2N2O3

310.3

cpsi-1306;2-(3-(2,4-Difluorophenyl)-4,5-dihydroisoxazol-5-yl)-1-morpholinoethan-1-one

DMSO:5 mg/mL (16.1 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years